Amgen Q1 2026 revenue rises 6% to $8.6B with 16 products growing double digits, boosting earnings and cash flow.

Amgen reported a 6% revenue increase to $8.6 billion in Q1 2026, driven by 16 products with double-digit sales growth despite patent expirations and competition. GAAP earnings per share rose 4% to $3.34, supported by higher operating income and strong product sales across multiple segments including general medicine, rare diseases, inflammation, and oncology. The company generated $1.5 billion in free cash flow and raised its dividend by 6%. Amgen is advancing several Phase 3 clinical trials and expects full-year 2026 revenues between $37.1 billion and $38.5 billion, with continued investment in R&D and strategic pipeline development.